Company Dossier · Health Care
Avantor
- Russell 1000
- MidCap 400
What Avantor is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to March 31, 2026: $6.55 billion, down 2.1% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to March 31, 2026: $0.44 billion, down 34% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to March 31, 2026: $0.13 billion, down 7.1% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.08 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2025: $1.11 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment 0.40 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 2 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 11, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q2 2026: $0.3 million on the open market.SEC Form 4
- 460 institutional managers reported a position at June 30, 2026 (+27 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 2 (5 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Avantor yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name Avantor, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralAvantor Inc (AVTR) Shares Surge 3.1% -- What GF Score of 71 Tells Investors
gurufocus.com · via Marketaux · Oct 5, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Sep 21, 20268-KDirector or officer changeItem 5.02
- Sep 21, 20268-KDirector or officer changeItem 5.02
- Aug 27, 20268-KDirector or officer changeItem 5.02
- Jul 17, 20268-KMaterial agreement signedItem 1.01
- Jun 16, 2026Patent
- Jun 9, 2026Patent
- May 12, 20268-KShareholder vote resultsItem 5.07
- Apr 23, 20268-KDirector or officer changeItem 5.02
- Apr 1, 20268-KDirector or officer changeItem 5.02
- Feb 25, 20268-KDirector or officer changeItem 5.02
- Feb 25, 20268-KDirector or officer changeItem 5.02
- Feb 17, 2026Patent
- Feb 11, 202610-KAnnual report (10-K)3 risk factors added, 0 removed
- Dec 18, 20258-KDirector or officer changeItem 5.02
- Dec 4, 20258-KDirector or officer changeItem 5.02
- Nov 10, 20258-KDirector or officer changeItem 5.02
- Oct 14, 20258-KMaterial agreement signedItem 1.01
- Oct 14, 20258-KMaterial agreement terminatedItem 1.02
- Oct 14, 20258-KDirector or officer changeItem 5.02
- Oct 3, 20258-KDirector or officer changeItem 5.02
- Sep 2, 2025Patent
- Aug 13, 20258-KDirector or officer changeItem 5.02
- Jul 21, 20258-KDirector or officer changeItem 5.02
- May 12, 20258-KDirector or officer changeItem 5.02
- May 12, 20258-KShareholder vote resultsItem 5.07
- Apr 28, 20258-KDirector or officer changeItem 5.02
- Apr 8, 2025Patent
- Feb 7, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Jan 8, 20258-KDirector or officer changeItem 5.02
- Nov 6, 20248-KDirector or officer changeItem 5.02
- Feb 14, 202410-KAnnual report (10-K)3 risk factors added, 1 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Edwards Lifesciences EW | $6.5B | $1.4B | Jun 30, 2026 |
| Encompass Health EHC | $6.2B | $0.4B | Jun 30, 2026 |
| Organon & Co. OGN | $6.1B | $0.6B | Jun 30, 2026 |
| Steris STE | $6.0B | $0.9B | Jun 30, 2026 |
| Agilent Technologies A | $7.4B | $1.3B | Jul 31, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Ensign Group ENSG | $5.5B | — | Jun 30, 2026 |
| Incyte INCY | $5.4B | — | Mar 31, 2026 |
Identity
- SEC CIK
- 1722482
- Wikidata
- Q104842834